Published in J Genet Syndr Gene Ther on January 01, 2013
Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol (2015) 1.00
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci (2008) 2.71
The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 2.71
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun (2007) 2.44
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res (1999) 2.32
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Sorting and processing of secretory proteins. Biochem J (1994) 1.65
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res (2008) 1.60
Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) (2006) 1.51
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50
Rab11 regulates exocytosis of recycling vesicles at the plasma membrane. J Cell Sci (2012) 1.41
Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.32
Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother (2011) 1.28
Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 1.28
EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem (2007) 1.22
Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res (2004) 1.21
The emerging role of the RAB25 small GTPase in cancer. Traffic (2009) 1.21
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res (2001) 1.20
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun (2007) 1.20
Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res (2002) 1.19
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol (2005) 1.18
Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci (2009) 1.14
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res (2007) 1.11
Polarized endocytic transport: the roles of Rab11 and Rab11-FIPs in regulating cell polarity. Histol Histopathol (2009) 1.09
Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol (2007) 1.09
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09
Resistance to TRAIL and how to surmount it. Immunol Res (2012) 1.08
Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells. J Immunol (2010) 1.07
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res (2004) 1.06
Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med (2012) 1.03
A 71-gene signature of TRAIL sensitivity in cancer cells. Mol Cancer Ther (2011) 1.03
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
Systems biology of apoptosis signaling networks. Curr Opin Biotechnol (2010) 1.01
Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des (2012) 0.97
Rab11 and its effector Rip11 participate in regulation of insulin granule exocytosis. Genes Cells (2009) 0.97
Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact. Semin Cancer Biol (2010) 0.95
Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules. Sci Rep (2011) 0.94
Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res (2012) 0.91
EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate (2009) 0.86